Skip to main content
    T

    Takeda Pharmaceutical Co Ltd ADR (TAK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $19.45
    +0.45 (+2.34%)

    Market Cap: $60.73B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(15/32)
    Avg Surprise
    +2975.66%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $1.2T
    Range$1.0T - $1.2T
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $1.2T
    Range$1.2T - $1.3T
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-N/A---
    Sep 26EST
    		-N/A---
    Jun 26
    Reported Jul 30
    		$0.48$0.41+17.07%Beat-99.7%
    Mar 26
    Reported May 13
    		$-0.74N/AN/ABeat-226.6%
    Dec 25
    Reported Jan 29
    		$0.21N/AN/ABeat+339.1%
    Sep 25
    Reported Oct 30
    		$-0.03N/A-116.75%Miss-100.1%
    Jun 25
    Reported Jul 30
    		$151.00$0.20+75174.18%Beat+78423.1%
    Mar 25
    Reported Jun 25
    		$-0.23$-0.17-37.11%Miss-3401.5%
    Dec 24
    Reported Jan 30
    		$0.05N/A-92.41%Miss-99.9%
    Sep 24
    Reported Oct 31
    		$29.07N/A-66.76%Miss+287.5%
    Jun 24
    Reported Jul 31
    		$0.19$0.12+56.60%Beat-99.3%
    Mar 24
    Reported May 9
    		$-0.01N/A+54.23%Beat-108.8%
    Dec 23
    Reported Feb 1
    		$33.79$0.11+31042.86%Beat+11444.2%
    Sep 23
    Reported Oct 26
    		$-15.50$0.14-10856.42%Miss-177.4%
    Jun 23
    Reported Jul 27
    		$28.76$18.62+54.46%Beat-15.3%
    Mar 23
    Reported May 11
    		$0.07$0.05+46.53%Beat+373.1%
    Dec 22
    Reported Feb 2
    		$0.29$0.29+0.93%Beat+82.4%
    Sep 22
    Reported Oct 27
    		$20.03N/A-70.34%Miss+490.4%
    Jun 22
    Reported Jul 28
    		$33.97$59.27-42.69%Miss-46.9%
    Mar 22
    Reported May 11
    		$-0.03N/A-144.72%Miss-100.0%
    Dec 21
    Reported Feb 3
    		$0.16$0.22-27.21%Miss-99.5%
    Sep 21
    Reported Oct 28
    		$-5.13N/A-105.29%Miss-471.7%
    Jun 21
    Reported Jul 30
    		$64.00$95.00-32.63%Miss+142.9%
    Mar 21
    Reported May 11
    		$63.08$88.00-28.32%Miss+11369.1%
    Dec 20
    Reported Feb 4
    		$29.78N/A-71.64%Miss+892.7%
    Sep 20
    Reported Oct 29
    		$1.38N/A-98.66%Miss+762.5%
    Jun 20
    Reported Jul 31
    		$26.35N/A-69.00%Miss+43015.3%
    Mar 20
    Reported May 13
    		$0.55$-0.21+361.90%Beat+188.7%
    Dec 19
    Reported Feb 4
    		$3.00N/A-96.00%Miss+1272.4%
    Sep 19
    Reported Oct 31
    		$0.16$-0.21+176.19%Beat-41.5%
    Jun 19
    Reported Jul 31
    		$-0.06N/A+67.68%Beat-113.7%
    Mar 19
    Reported May 14
    		$-0.62$-0.36-72.22%Miss-97.3%
    Dec 18
    Reported Feb 1
    		$0.22$0.10+118.60%Beat-45.1%
    Sep 18
    Reported Oct 31
    		$0.27$0.23+18.96%Beat+74.3%
    Jun 18
    Reported Jul 31
    		$0.45$0.31+44.13%Beat-46.6%
    Mar 18
    Reported May 14
    		$-0.31$-0.37+15.08%Beat-10.4%
    Dec 17
    Reported Feb 1
    		$0.40N/AN/ABeat+68.9%
    Sep 17
    Reported Nov 1
    		$0.16N/AN/ABeat-
    Jun 17
    Reported Jul 28
    		$0.84N/AN/ABeat-
    Mar 17
    Reported Jun 29
    		$-0.28N/AN/ABeat-
    Dec 16
    Reported Mar 30
    		$0.24N/AN/ABeat-

    Dividends

    Dividend Metrics

    Forward Yield3.24%
    Forward Annual Dividend$0.63
    Payout Ratio15.98%
    FrequencySemi-Annual
    Pay MonthsJul, Dec

    Growth

    3Y CAGR-3.21%
    5Y CAGR-6.78%
    TAK dividend history and ex-dividend datesRun TAK in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio-247.20EV/EBITDA10.89x
    Price/FCF16.97xFCF Yield5.89%
    Profitability
    Profit Margin-3.54%Operating Margin16.50%
    ROE-2.26%ROIC3.22%
    Financial Health
    Debt/Equity0.65xInterest Coverage1.85x
    Current Ratio1.14xQuick Ratio0.62x
    Trading Statistics
    Beta0.10Avg Volume2.72M
    52-Week High$19.0452-Week Low$12.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.51
    SMA 20$18.58
    SMA 50$18.28
    SMA 200$17.23
    EMA 10$18.72
    EMA 20$18.57
    EMA 50$18.21
    EMA 200$17.03

    MACD

    Line: 0.17Signal: 0.09Hist: 0.08

    ADX

    ADX: 22.5+DI: 43.0-DI: 17.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down68.0
    PSAR$17.96

    Bollinger Bands

    Upper Band$19.45
    Lower Band$17.70
    %B Position941%(Upper)
    Band Width1.00

    RSI (14-Day)

    Neutral
    66.9

    Momentum Oscillators

    Stoch %K79.6
    Stoch %D76.0
    Williams %R-20.3
    ROC (10d)8.9%
    Momentum1.59
    CCI (20d)199.7
    MFI (14d)61.7

    Volatility Measures

    ATR (14d)$0.35(1.8%)
    StdDev (20d)0.44
    Hist Vol21.6%(Moderate)

    Volume Flow

    VWAP$19.60
    OBV85.2M
    AD Line-3.5B
    CMF (20d)-0.026

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio1.5x(High)
    VWMA (20d)$18.60

    Pivot Points

    R3$19.65
    R2$19.34
    R1$19.18
    Pivot Point$18.87
    S1$18.71
    S2$18.40
    S3$18.24

    Advanced Oscillators

    TSI12.26
    Ultimate Osc60.3
    KST6.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1219.90B$1114.65B$1213.21B$1112.80B$1106.68B$1053.40B$1144.12B$1176.04B$1207.99B$1050.87B$1111.19B$1043.09B
    Cost of Revenue$406.68B$570.84B$552.87B$380.06B$384.68B$382.10B$416.87B$394.31B$386.95B$387.33B$379.48B$343.58B
    Gross Profit$813.22B$543.81B$660.35B$732.74B$722.01B$671.30B$727.25B$781.73B$821.04B$663.54B$731.71B$699.51B
    Operating Expenses$611.81B$496.27B$466.28B$663.74B$537.44B$746.20B$660.31B$597.48B$654.71B$673.61B$626.79B$748.85B
    R&D$167.40B$198.91B$178.39B$161.48B$143.89B$216.00B$170.19B$175.56B$168.46B$195.86B$187.38B$183.95B
    SG&A$286.51B$292.00B$282.78B$253.55B$255.88B$295.87B$270.59B$268.28B$270.03B$285.23B$267.52B$252.95B
    Operating Income$201.42B$47.54B$194.06B$69.00B$184.57B$-74,900,000,000$66.94B$184.25B$166.33B$-10,069,000,000$104.91B$-49,341,000,000
    Interest Income$24.61B$189.15B$87.87B$44.40B$33.94B$32.37B$40.54B$4.12B$30.68B$34.81B$21.79B$46.64B
    Interest Expense$63.84B$44.45B$125.86B$83.14B$107.16B$330.20M$207.35M$68.45B$59.69B$317.81M$66.57B$401.37M
    Income Before Tax$162.72B$-53,443,096,000$136.28B$28.17B$150.63B$-107,300,000,000$26.41B$119.37B$136.60B$-47,522,000,000$61.26B$-95,980,000,000
    Income Tax Expense$49.46B$-28,740,469,000$30.67B$39.90B$26.35B$-4,200,000,000$2.57B$27.27B$41.30B$-44,528,000,000$-44,496,000,000$-48,009,000,000
    Net Income$113.20B$-24,765,767,000$105.51B$-11,802,000,000$124.24B$-103,200,000,000$23.79B$92.05B$95.25B$-3,018,000,000$105.72B$-48,030,000,000
    EBITDA$389.20B$154.88B$452.78B$296.29B$439.42B$181.27B$193.01B$380.28B$388.51B$342.78B$257.03B$144.74B
    EBIT$226.56B$-8,992,216,000$262.14B$111.31B$257.79B$-8,500,000,000$6.05B$187.83B$196.29B$156.03B$69.97B$-37,958,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Toll Booth on Biotech’s Highway: Why Halozyme’s Royalty Engine Could Make Patient Investors Rich

    Halozyme's ENHANZE platform is a toll booth on injectable biologics: partners develop drugs, HALO collects royalties on every dose sold across 10 commercialized products in 100+ global markets. Three major deals in 100 days: Elektrofi acquisition ($750M+ in Oct), Skye Bioscience (Jan 5)...

    Glenn Ford
    •
    1/14/26
    •
    188
    Biotech, value investing, Healthcare Stocks
    Also mentions:
    TAKJNJ

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside

    Analysts have raised the average 12-month price target for Takeda Pharmaceutical Company Limited (NYSE: TAK) stock from $20.58 to $20.74...

    TradingView•10/15/26•Bullish

    Takeda (TAK) Launches ORZEYFUL for Narcolepsy Type 1 in Japan and China

    Takeda Pharmaceutical Co Ltd (TAK) has launched ORZEYFUL (oveporexton), a novel treatment for narcolepsy type 1...

    GuruFocus•10/14/26•Somewhat-Bullish

    Takeda Pharmaceutical stock trades at 52.50 times earnings

    Takeda Pharmaceutical stock traded at a P/E ratio of 52.50 on October 14, 2026, with a market capitalization of JPY 9.4 trillion. The stock closed at JPY 5,889 on the Tokyo Stock Exchange...

    ad-hoc-news.de•10/14/26•Neutral

    Takeda reports psoriasis data: Takeda Pharmaceutical stock sits 3.04 percent below its high

    Takeda Pharmaceutical reported positive Phase 3 data for its psoriasis drug, zasocitinib, showing 36.50% complete skin clearance compared to 13.90% for a comparator. This strengthens Takeda's pipeline as regulators...

    ad-hoc-news.de•10/14/26•Bullish

    How Investors May Respond To Takeda (TSE:4502) Phase 3 Psoriasis Win

    Takeda Pharmaceutical announced positive Phase 3 data for its oral TYK2 inhibitor, zasocitinib, in treating moderate to severe plaque psoriasis...

    Simply Wall Street•10/13/26•Bullish

    TAK Valuation and Fair Value

    P/E
    -247.2x
    Forward P/E
    11.5x
    EV/EBITDA
    10.9x
    P/FCF
    17.0x
    PEG
    0.4x
    P/B
    1.3x
    See GNG's fair value

    TAK Profitability: Margins, ROIC and FCF

    Gross margin
    59.1%
    Operating margin
    16.5%
    Net margin
    -3.5%
    ROIC
    3.2%
    ROE
    -2.3%
    FCF margin
    1880.8%
    FCF yield
    5.9%

    TAK Competitors

    CompanyTicker
    Boston Scientific CorpBSX
    Cardinal Health IncCAH
    Cencora Inc.COR
    Natera IncNTRA
    Cigna CorpCI
    Becton Dickinson and CompanyBDX
    Regeneron Pharmaceuticals IncREGN
    Humana IncHUM

    Sector: Healthcare

    TAK Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TAK Bull Case vs Bear Case

    Bull case

    • TAK converts 1880.8% of revenue into free cash flow.
    • TAK grew quarterly revenue 10.2% year over year.

    Bear case

    • TAK has a -3.5% net profit margin.

    TAK Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -26.4%

    TAK Dividend

    Forward yield
    3.2%
    Payout ratio
    16.0%
    3Y DPS growth
    -3.2%
    5Y DPS growth
    -6.8%
    Pay months
    Jul, Dec
    TAK dividend history

    Frequently Asked Questions About TAK

    What is TAK's current dividend yield?

    Takeda Pharmaceutical Co Ltd ADR (TAK) has a forward dividend yield of 3.24%.

    Does TAK pay dividends?

    Yes, Takeda Pharmaceutical Co Ltd ADR pays dividends with a forward dividend yield of 3.24%.

    What is TAK's market cap?

    Takeda Pharmaceutical Co Ltd ADR (TAK) has a market capitalization of $60.73B with a current stock price of $19.45.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In